title: Melanoma, version 2.2013: featured updates to the NCCN guidelines.
abstract: The NCCN Guidelines for Melanoma provide multidisciplinary recommendations on the clinical management of patients with melanoma. This NCCN Guidelines Insights report highlights notable recent updates. Foremost of these is the exciting addition of the novel agents ipilimumab and vemurafenib for treatment of advanced melanoma. The NCCN panel also included imatinib as a treatment for KIT-mutated tumors and pegylated interferon alfa-2b as an option for adjuvant therapy. Also important are revisions to the initial stratification of early-stage lesions based on the risk of sentinel lymph node metastases, and revised recommendations on the use of sentinel lymph node biopsy for low-risk groups. Finally, the NCCN panel reached clinical consensus on clarifying the role of imaging in the workup of patients with melanoma.
authors.affiliation: Memorial Sloan-Kettering Cancer Center.
authors.forename: Daniel G
authors.initials: DG
authors.lastname: Coit
authors.forename: Robert
authors.initials: R
authors.lastname: Andtbacka
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Anker
authors.forename: Christopher K
authors.initials: CK
authors.lastname: Bichakjian
authors.forename: William E
authors.initials: WE
authors.lastname: Carson
authors.forename: Adil
authors.initials: A
authors.lastname: Daud
authors.forename: Dominick
authors.initials: D
authors.lastname: Dimaio
authors.forename: Martin D
authors.initials: MD
authors.lastname: Fleming
authors.forename: Valerie
authors.initials: V
authors.lastname: Guild
authors.forename: Allan C
authors.initials: AC
authors.lastname: Halpern
authors.forename: F Stephen
authors.initials: FS
authors.lastname: Hodi
authors.forename: Mark C
authors.initials: MC
authors.lastname: Kelley
authors.forename: Nikhil I
authors.initials: NI
authors.lastname: Khushalani
authors.forename: Ragini R
authors.initials: RR
authors.lastname: Kudchadkar
authors.forename: Julie R
authors.initials: JR
authors.lastname: Lange
authors.forename: Anne
authors.initials: A
authors.lastname: Lind
authors.forename: Mary C
authors.initials: MC
authors.lastname: Martini
authors.forename: Anthony J
authors.initials: AJ
authors.lastname: Olszanski
authors.forename: Scott K
authors.initials: SK
authors.lastname: Pruitt
authors.forename: Merrick I
authors.initials: MI
authors.lastname: Ross
authors.forename: Susan M
authors.initials: SM
authors.lastname: Swetter
authors.forename: Kenneth K
authors.initials: KK
authors.lastname: Tanabe
authors.forename: John A
authors.initials: JA
authors.lastname: Thompson
authors.forename: Vijay
authors.initials: V
authors.lastname: Trisal
authors.forename: Marshall M
authors.initials: MM
authors.lastname: Urist
authors.forename: Nicole
authors.initials: N
authors.lastname: McMillian
authors.forename: Maria
authors.initials: M
authors.lastname: Ho
mesh_terms: D000465:Algorithms; D017024:Chemotherapy, Adjuvant; D003191:Comprehensive Health Care / Q000458:organization & administration; D018450:Disease Progression; D004502:Education, Medical, Continuing / Q000331:legislation & jurisprudence; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008495:Medical Oncology / Q000458:organization & administration; D008545:Melanoma / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D021701:Sentinel Lymph Node Biopsy / Q000193:education / Q000379:methods; D012878:Skin Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D012955:Societies, Medical / Q000331:legislation & jurisprudence / Q000458:organization & administration; D035703:Therapies, Investigational / Q000379:methods
chemical_list: D007372:Interferons